NO930731L - kininogenase inhibitor - Google Patents
kininogenase inhibitorInfo
- Publication number
- NO930731L NO930731L NO93930731A NO930731A NO930731L NO 930731 L NO930731 L NO 930731L NO 93930731 A NO93930731 A NO 93930731A NO 930731 A NO930731 A NO 930731A NO 930731 L NO930731 L NO 930731L
- Authority
- NO
- Norway
- Prior art keywords
- amino acid
- group
- analog
- amide
- conformational
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0227—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the (partial) peptide sequence -Phe-His-NH-(X)2-C(=0)-, e.g. Renin-inhibitors with n = 2 - 6; for n > 6 see C07K5/06 - C07K5/10
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Genetics & Genomics (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Kininogenaseinhibitorer, som optimalt ikke overskrider størrelsen av et heksapeptid, represen-tert ved (II), hvor A og B = aminoacyl (omfattende aminoacylanalog) som er de samme eller forskjellige og danner en dipeptidgruppe hvor aminosyren A "har en terminalgruppe og er en hvilken som helst amino- eller iminosyrerest (men fortrinnsvis med D-konfigurasjon, og B er en lipofil aminosyrerest med D- eller L-konfigurasjon, men ikke prolin eller en prolinanalog, eller en konformasjonsanalog av nevnte dipeptidgruppe hvor peptidbindingen er erstattet med -CH-NH- ("redusert"), -CH(OH)-CH- ("hydroksy"), -CO-CH("keto"), -CHCH- ("hydrokarbon") eller en annen konformasjonsetterligning av peptidbindingen og i (III) skal sidekjeden Rvære sidekjeden i en basisk aminosyre eller aminosyreanalog (fortrinnsvis med L-konfigurasjon), og R være H eller lavere alkyl(0-0) eller C eller peptidbindingen omfattende -N(R)- er erstattet, hvilket farer til en konformasjonsetterligning som ovenfor; V = en bindingsøkende eller karbonylaktiverende gruppe, fortrinnsvis valgt fra H (når A eller B må være cykloheksylalanin, fortrinnsvis D dersom den er A eller L dersom den er B) eller alkyl (CCq) eller fluoralkyl (C-C); substituert oksymetylen; tiometylen; sulfoksymetylen; sulfonylmetylen; aminometylen; hydrazino-metylen; -CH-Het (hvor Het = en substituert eller usubstituert heterocyklus); substituert amino (men når den resulterende forbindelse er et sekundært alkylamid, må B ikke være fenylalanin); en aminosyregruppe eller dens ester eller amid; et karboksylisk sekundært amid eller primært amid, når B må være cykloheksylalanin eller adamantylalanin eller en annen svær lipofil, ikke-aromatisk aminosyre (ikke Ala Leu Ile Val Nva Met Nie Phe Tyr Trp Nal (1)); tertiært karboksamid; karboksyalkylgruppe eller dens ester eller amid eller aminoacylderivat.Quininogenase inhibitors, which optimally do not exceed the size of a hexapeptide, represented by (II), wherein A and B = aminoacyl (comprising aminoacyl analog) which are the same or different and form a dipeptide group where amino acid A "has a terminal group and is a any amino or amino acid residue (but preferably with D-configuration, and B is a lipophilic amino acid residue with D- or L-configuration, but not proline or a proline analog, or a conformational analog of said dipeptide group in which the peptide bond is replaced by -CH-NH - ("reduced"), -CH (OH) -CH- ("hydroxy"), -CO-CH ("keto"), -CHCH- ("hydrocarbon") or other conformational imitation of the peptide bond and in (III) the side chain R should be the side chain of a basic amino acid or amino acid analog (preferably with L-configuration), and R is H or lower alkyl (0-0) or C or the peptide bond comprising -N (R) - is replaced, leading to a conformational imitation which above; V = a binding search nd or carbonyl activating group, preferably selected from H (when A or B must be cyclohexylalanine, preferably D if it is A or L if it is B) or alkyl (Cqq) or fluoroalkyl (C-C); substituted oxymethylene; thiomethylene; sulfoxymethylene; sulfonylmethylene; aminomethylene; hydrazinomethylene; -CH-Het (wherein Het = a substituted or unsubstituted heterocycle); substituted amino (but when the resulting compound is a secondary alkylamide, B must not be phenylalanine); an amino acid group or its ester or amide; a carboxylic secondary amide or primary amide, when B must be cyclohexylalanine or adamantylalanine or another major lipophilic, non-aromatic amino acid (not Ala Leu Ile Val Nva Met Nie Phe Tyr Trp Nal (1)); tertiary carboxamide; carboxyalkyl group or its ester or amide or aminoacyl derivative.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB909019558A GB9019558D0 (en) | 1990-09-07 | 1990-09-07 | Enzyme inhibitors |
PCT/GB1991/001479 WO1992004371A1 (en) | 1990-09-07 | 1991-09-02 | Kininogenase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
NO930731D0 NO930731D0 (en) | 1993-02-26 |
NO930731L true NO930731L (en) | 1993-05-07 |
Family
ID=10681831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO93930731A NO930731L (en) | 1990-09-07 | 1993-02-26 | kininogenase inhibitor |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP0652893A1 (en) |
JP (1) | JPH06501461A (en) |
AU (1) | AU8438791A (en) |
CA (1) | CA2090858A1 (en) |
FI (1) | FI930946A (en) |
GB (1) | GB9019558D0 (en) |
HU (1) | HUT64084A (en) |
IE (1) | IE913120A1 (en) |
MC (1) | MC2313A1 (en) |
NO (1) | NO930731L (en) |
PT (1) | PT98885A (en) |
WO (1) | WO1992004371A1 (en) |
ZA (1) | ZA917096B (en) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9103612D0 (en) * | 1991-12-04 | 1991-12-04 | Astra Ab | NEW PEPTIDE DERIVATIVES |
US5374623A (en) * | 1992-08-20 | 1994-12-20 | Prototek, Inc. | Cysteine protease inhibitors effective for in vivo use |
SE9301911D0 (en) * | 1993-06-03 | 1993-06-03 | Ab Astra | NEW PEPTIDE DERIVATIVES |
SE9301916D0 (en) * | 1993-06-03 | 1993-06-03 | Ab Astra | NEW PEPTIDES DERIVATIVES |
US5783563A (en) * | 1993-06-03 | 1998-07-21 | Astra Aktiebolag | Method for treatment or prophylaxis of venous thrombosis |
US6984627B1 (en) | 1993-06-03 | 2006-01-10 | Astrazeneca Ab | Peptide derivatives |
GB9318637D0 (en) * | 1993-09-08 | 1993-10-27 | Ferring Res Ltd | Enzyme inhibitors |
US5486623A (en) | 1993-12-08 | 1996-01-23 | Prototek, Inc. | Cysteine protease inhibitors containing heterocyclic leaving groups |
SE9404196D0 (en) * | 1994-12-02 | 1994-12-02 | Astra Ab | New antithrombotic formulation |
US5696231A (en) * | 1994-12-21 | 1997-12-09 | Corvas International, Inc. | N-substituted glycine derivatives as enzyme inhibitors |
US6025472A (en) * | 1994-12-21 | 2000-02-15 | Corvas International, Inc. | N-substituted glycine derivatives as enzyme inhibitors |
CZ132798A3 (en) * | 1995-10-30 | 1999-02-17 | Smithkline Beecham Corporation | Protease inhibitors |
US6586466B2 (en) | 1995-10-30 | 2003-07-01 | Smithkline Beecham Corporation | Carbohydrazide-protease inhibitors |
TWI238827B (en) | 1995-12-21 | 2005-09-01 | Astrazeneca Ab | Prodrugs of thrombin inhibitors |
US6417161B1 (en) | 1998-04-24 | 2002-07-09 | 3-Dimensional Pharmaceuticals, Inc. | Amino acid amidinohydrazones, alkoxyguanidines and aminoguanidines as protease inhibitors |
YU42401A (en) | 1998-12-14 | 2003-12-31 | Ortho-Mcneil Pharmaceuticals Inc. | Substituted heterociclic acyl-tripeptides useful as thrombin receptor modulators |
US20030144175A1 (en) | 1998-12-23 | 2003-07-31 | Smithkline Beecham Corporation | Protease inhibitors |
EP1930021A3 (en) | 1999-02-18 | 2008-06-18 | Kaken Pharmaceutical Co., Ltd. | Novel amide derivatives as growth hormone secretagogues |
US6583137B1 (en) | 1999-11-10 | 2003-06-24 | Smithkline Beecham Corporation | Protease inhibitors |
WO2001034599A1 (en) | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
JP2003513924A (en) | 1999-11-10 | 2003-04-15 | スミスクライン・ビーチャム・コーポレイション | Protease inhibitor |
CN1416346A (en) | 2000-03-21 | 2003-05-07 | 史密丝克莱恩比彻姆公司 | Peotease inhibitors |
GB0205527D0 (en) * | 2002-03-08 | 2002-04-24 | Ferring Bv | Inhibitors |
JP2006511452A (en) | 2002-07-03 | 2006-04-06 | バイオ サイエンス インターナショナル インコーポレイテッド | Peptide containing aromatic D-amino acid and method of using the same |
FR2846969A1 (en) * | 2002-11-08 | 2004-05-14 | Salles Jean Pierre | New modified active agent derivatives with improved bioavailability comprising parent drug, e.g. anticancer agent, plus fluorinated hydrocarbon chain and recognition or hydrophilizing moiety |
EP1736465A4 (en) | 2004-03-31 | 2009-06-17 | Ajinomoto Kk | Aniline derivatives |
GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
GB2494851A (en) | 2011-07-07 | 2013-03-27 | Kalvista Pharmaceuticals Ltd | Plasma kallikrein inhibitors |
GB201212081D0 (en) | 2012-07-06 | 2012-08-22 | Kalvista Pharmaceuticals Ltd | New polymorph |
IL239682B (en) | 2013-01-08 | 2018-10-31 | Kalvista Pharmaceuticals Ltd | Benzylamine and 2-(aminomethyl)pyridine derivatives |
GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
GB2510407A (en) | 2013-02-04 | 2014-08-06 | Kalvista Pharmaceuticals Ltd | Aqueous suspensions of kallikrein inhibitors for parenteral administration |
RU2712621C2 (en) | 2013-05-23 | 2020-01-30 | Калвиста Фармасьютикалз Лимитед | Nitrogen-containing heterocyclic derivatives useful as plasma kallikrein inhibitor |
GB2517908A (en) | 2013-08-14 | 2015-03-11 | Kalvista Pharmaceuticals Ltd | Bicyclic inhibitors |
TWI636047B (en) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | Heterocyclic derivatives |
CN105683179B (en) | 2013-08-14 | 2018-10-26 | 卡尔维斯塔制药有限公司 | The inhibitor of plasma kallikrein |
RU2728785C2 (en) | 2014-10-06 | 2020-07-31 | Кортексим, Инк. | Inhibitors of lysine-specific gingipain |
GB201421088D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
JP6877424B2 (en) | 2015-11-09 | 2021-05-26 | コーテクシーミー, インコーポレイテッド | Inhibitor of arginine gingipain |
KR20220107319A (en) | 2016-05-31 | 2022-08-02 | 칼비스타 파마슈티컬즈 리미티드 | Pyrazole derivatives as plasma kallikrein inhibitors |
GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
TWI787202B (en) | 2016-09-16 | 2022-12-21 | 美商昆斯治療公司 | Ketone inhibitors of lysine gingipain |
CN107011217B (en) * | 2017-03-24 | 2018-08-14 | 东华大学 | A kind of fat-soluble 5-ALA derivative and its preparation method and application |
CN107043338B (en) * | 2017-03-24 | 2018-09-25 | 东华大学 | A kind of 5-ALA derivative and its preparation method and application |
GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
HRP20220367T1 (en) | 2017-11-29 | 2022-05-27 | Kalvista Pharmaceuticals Limited | Dosage forms comprising a plasma kallikrein inhibitor |
GB201910116D0 (en) | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of hereditary angioedema |
GB201910125D0 (en) | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of angioedema |
EP4010333A1 (en) | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
GB201918994D0 (en) | 2019-12-20 | 2020-02-05 | Kalvista Pharmaceuticals Ltd | Treatments of diabetic macular edema and impaired visual acuity |
GB2591730A (en) | 2019-12-09 | 2021-08-11 | Kalvista Pharmaceuticals Ltd | New polymorphs |
WO2022079446A1 (en) | 2020-10-15 | 2022-04-21 | Kalvista Pharmaceuticals Limited | Treatments of angioedema |
EP4232031A1 (en) | 2020-10-23 | 2023-08-30 | Kalvista Pharmaceuticals Limited | Treatments of angioedema |
WO2022172006A1 (en) | 2021-02-09 | 2022-08-18 | Kalvista Pharmaceuticals Limited | Treatments of hereditary angioedema |
WO2023002219A1 (en) | 2021-07-23 | 2023-01-26 | Kalvista Pharmaceuticals Limited | Treatments of hereditary angioedema |
WO2023209381A1 (en) | 2022-04-27 | 2023-11-02 | Kalvista Pharmaceuticals Limited | Formulations of a plasma kallikrein inhibitor |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2964956D1 (en) * | 1978-07-18 | 1983-04-07 | Kabi Ab | Bradykinin inhibiting tripeptide derivatives, process for their preparation and pharmaceutical preparations containing them |
US4563305A (en) * | 1981-01-07 | 1986-01-07 | University Of Miami | Radiolabelled substrates for assaying mammalian enzymes |
US4835253A (en) * | 1987-04-03 | 1989-05-30 | The University Hospital | Specific inhibitors of tissue kallikrein |
ZA897515B (en) * | 1988-10-07 | 1990-06-27 | Merrell Dow Pharma | Novel peptidase inhibitors |
-
1990
- 1990-09-07 GB GB909019558A patent/GB9019558D0/en active Pending
-
1991
- 1991-09-02 AU AU84387/91A patent/AU8438791A/en not_active Abandoned
- 1991-09-02 MC MC912313D patent/MC2313A1/en unknown
- 1991-09-02 HU HU93610A patent/HUT64084A/en unknown
- 1991-09-02 EP EP91915557A patent/EP0652893A1/en not_active Withdrawn
- 1991-09-02 JP JP3514802A patent/JPH06501461A/en active Pending
- 1991-09-02 WO PCT/GB1991/001479 patent/WO1992004371A1/en not_active Application Discontinuation
- 1991-09-02 CA CA002090858A patent/CA2090858A1/en not_active Abandoned
- 1991-09-05 IE IE312091A patent/IE913120A1/en unknown
- 1991-09-06 ZA ZA917096A patent/ZA917096B/en unknown
- 1991-09-06 PT PT98885A patent/PT98885A/en not_active Application Discontinuation
-
1993
- 1993-02-26 NO NO93930731A patent/NO930731L/en unknown
- 1993-03-03 FI FI930946A patent/FI930946A/en unknown
Also Published As
Publication number | Publication date |
---|---|
NO930731D0 (en) | 1993-02-26 |
AU8438791A (en) | 1992-03-30 |
CA2090858A1 (en) | 1992-03-08 |
FI930946A0 (en) | 1993-03-03 |
HU9300610D0 (en) | 1993-05-28 |
FI930946A (en) | 1993-04-26 |
PT98885A (en) | 1992-08-31 |
EP0652893A1 (en) | 1995-05-17 |
IE913120A1 (en) | 1992-03-11 |
WO1992004371A1 (en) | 1992-03-19 |
ZA917096B (en) | 1992-04-29 |
GB9019558D0 (en) | 1990-10-24 |
JPH06501461A (en) | 1994-02-17 |
HUT64084A (en) | 1993-11-29 |
MC2313A1 (en) | 1993-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO930731L (en) | kininogenase inhibitor | |
GB1586521A (en) | Analgesic tetrapeptides and pentapeptides | |
US5484771A (en) | Antiherpes peptide derivatives having a 1,4-dioxo-C, N-terminus | |
US4439360A (en) | Retro-inverso analogues of C-terminal penta and hexapeptides of Substance P | |
AU5963290A (en) | Inhibition of the n-end rule pathway in living cells | |
Ondetti | Citrulline-containing analogs of bradykinin | |
WO1992017025A3 (en) | GnRH analogs | |
EP0161007A2 (en) | Retro - inverso C-Terminal hexapeptide analogues of substance P | |
US4104371A (en) | Psychopharmacologically active peptides and peptide-derivatives, and the use thereof | |
KR840001668B1 (en) | Process for the preparation of peptides | |
SG171348A1 (en) | Tumor necrosis factor alpha inhibiting peptides and uses thereof | |
GB1584968A (en) | Pentapeptides processes for their preparation and pharmaceutical compositions containing them | |
US4322342A (en) | Analgesic compounds | |
US5700780A (en) | Antiviral peptide derivatives having a 2-oxoalkyl amino acid side chain | |
Jarvis et al. | Structure of the cell wall of Staphylococcus aureus. VIII. Structure and chemical synthesis of the basic peptides released by the Myxobacterium enzyme | |
US5312811A (en) | Peptide derivatives and antidemetia agents | |
US3973006A (en) | Peptide enzyme inhibitors of angiotensin I | |
Sugano et al. | Studies of peptide antibiotics. XXX. Syntheses of gramicidin S analogs containing N-methylleucine in place of leucine | |
GB1587427A (en) | Polypeptide derivatives | |
KR920701180A (en) | 4H-3,1-benzoxazin-4-one compound and pharmaceutical composition for inhibiting elastase thereof | |
US3268502A (en) | Undecapeptides | |
WO1988005049A1 (en) | Novel compounds | |
US4087419A (en) | Heptapeptides and methods for their production | |
Byk et al. | Synthesis and conformational analysis of peptide inhibitors of farnesyltransferase | |
HU181402B (en) | Process for preparing new peptides with psychopharmacological activity |